Immunocore Holdings Ltd (IMCR) - Total Liabilities
Based on the latest financial reports, Immunocore Holdings Ltd (IMCR) has total liabilities worth $705.94 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Immunocore Holdings Ltd - Total Liabilities Trend (2018–2024)
This chart illustrates how Immunocore Holdings Ltd's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Immunocore Holdings Ltd to evaluate short-term liquidity relative to the company's equity base.
Immunocore Holdings Ltd Competitors by Total Liabilities
The table below lists competitors of Immunocore Holdings Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Zhongchao Cable Co Ltd
SHE:002471
|
China | CN¥3.56 Billion |
|
Fujian Expressway Development Co Ltd
SHG:600033
|
China | CN¥2.47 Billion |
|
Blackrock Innovation & Growth Trust
NYSE:BIGZ
|
USA | $28.59 Million |
|
Opera Limited
F:2V8
|
Germany | €151.97 Million |
|
Orizon Valorização de Resíduos S.A
SA:ORVR3
|
Brazil | R$2.69 Billion |
|
Orange Belgium SA
BR:OBEL
|
Belgium | €3.09 Billion |
|
Eramet SA
PA:ERA
|
France | €4.39 Billion |
|
Cogeco Communications Inc
TO:CCA
|
Canada | CA$5.92 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Immunocore Holdings Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Immunocore Holdings Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immunocore Holdings Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immunocore Holdings Ltd (2018–2024)
The table below shows the annual total liabilities of Immunocore Holdings Ltd from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $648.79 Million | +184.36% |
| 2023-12-31 | $228.16 Million | +21.45% |
| 2022-12-31 | $187.86 Million | +6.89% |
| 2021-12-31 | $175.76 Million | +23.91% |
| 2020-12-31 | $141.85 Million | -37.34% |
| 2019-12-31 | $226.37 Million | +62.63% |
| 2018-12-31 | $139.19 Million | -- |
About Immunocore Holdings Ltd
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat adv… Read more